Lantheus Holdings, Inc. (LNTH)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
PYLARIFY Revenue	972.39M	989.12M	1.06B
PYLARIFY Revenue Growth	-1.69%	-6.50%	24.26%
Other Radiopharmaceutical Oncology Revenue	-	-	384.00K
Other Radiopharmaceutical Oncology Revenue Growth	-	-	-87.73%
Total Radiopharmaceutical Oncology Revenue	972.39M	989.12M	1.06B
Total Radiopharmaceutical Oncology Revenue Growth	-1.69%	-6.53%	23.85%
DEFINITY Revenue	335.66M	330.25M	317.79M
DEFINITY Revenue Growth	1.64%	3.92%	13.59%
Neuraceq Revenue	-	51.45M	-
TechneLite Revenue	-	86.80M	95.49M
TechneLite Revenue Growth	-	-9.09%	9.29%
Other Precision Diagnostics Revenue	-	24.62M	24.23M
Other Precision Diagnostics Revenue Growth	-	1.59%	5.44%
Total Precision Diagnostics Revenue	508.82M	493.11M	437.51M
Total Precision Diagnostics Revenue Growth	3.18%	12.71%	12.15%
Strategic Partnerships and Other Revenue	64.98M	59.38M	38.18M
Strategic Partnerships and Other Revenue Growth	9.42%	55.52%	-26.40%
Revenue (Other)	-1.31B	-1.48B	-1.50B
Revenue (Total)	1.55B	1.54B	1.53B
Revenue (Total) Growth	0.30%	0.50%	18.32%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Product Revenue	1.51B	1.51B	1.52B
Product Revenue Growth	0.19%	-1.13%	20.72%
License and Royalty Revenue	35.67M	34.04M	9.13M
License and Royalty Revenue Growth	4.81%	272.88%	-72.64%
Revenue (Total)	1.55B	1.54B	1.53B
Revenue (Total) Growth	0.30%	0.50%	18.32%

Updated May 7, 2026. Data Source: Fiscal.ai.